FDA's formation of an internal Transparency Task Force is a savvy approach that allows agency leaders to begin making good now on their pledges to enhance openness while giving them six months to decide whether to release any specific new information
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
President Trump’s new Executive Order on drug pricing reprises several policy themes from his first administration, including giving the FDA many tasks intended to increase competition in the marketplace.
FDA Commissioner Martin Makary will give industry a new avenue for access and influence despite his and HHS Secretary Robert F. Kennedy Jr.’s claims that the pharma-FDA relationship is too cozy.
The European Medicines Agency’s chief medical officer Steffen Thistrup argued that patients are able to understand the “complex regulatory and scientific issues” that the EMA committees discuss when they assess drugs.
